DUBLIN--(BUSINESS WIRE)--The "Global Bi-Specific Antibodies Market Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
According to the report, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period.
The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing incidences of diseases and increasing demand for effective treatment, for the Global Bi-Specific Antibodies Market. Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs.
Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
The prominent players in Global Bi-Specific Antibodies Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Bi-Specific Antibodies Market.
Key Topics Covered:
1. Research View
2. Research Methodology
3. Bi-Specific Antibodies - An Introduction
4. Global Bi-Specific Antibodies Market Outlook to 2022
5. Bi-Specific Antibodies Pipeline Analysis
6. Market Dynamics
7. Current Status of Major Bi-Specific Antibodies in Pipeline
8. Trends and Developments
9. Strategic Collaborations in the Bi-Specific Antibodies Industry
10. Competitive Assessment
- AbbVie Inc.
- Amgen Inc.
- Aptevo Therapeutics Inc.
- F. Hoffman La Roche Ltd.
- Fresenius SE & Co. KGaA
- Glenmark Pharmaceuticals Limited
- Ligand Pharmaceuticals, Inc.
- MacroGenics, Inc.
- Merus N.V.
- OncoMed Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- Xencor, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/s7w92r/global?w=4